Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/36834
Title: Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality
Authors: VERBRUGGE, Frederik 
Omote, Kazunori
Reddy, Yogesh N., V
Sorimachi, Hidemi
Obokata, Masaru
Borlaug, Barry A.
Issue Date: 2022
Publisher: OXFORD UNIV PRESS
Source: EUROPEAN HEART JOURNAL, 43 (20), p. 1941-1951
Abstract: Background A substantial proportion of patients with heart failure (HF) with preserved ejection fraction (HFpEF) present with normal natriuretic peptide (NP) levels. The pathophysiology and natural history for this phenotype remain unclear. Methods and results Consecutive subjects undergoing invasive cardiopulmonary exercise testing for unexplained dyspnoea at Mayo Clinic in 2006-18 were studied. Heart failure with preserved ejection fraction was defined as a pulmonary arterial wedge pressure (PAWP) >= 15 mmHg (rest) or >= 25 mmHg (exercise). Patients with HFpEF and normal NP [N-terminal of the pro-hormone B-type natriuretic peptide (NT-proBNP) < 125 ng/L] were compared with HFpEF with high NP (NT-proBNP >= 125 ng/L) and controls with normal haemodynamics. Patients with HFpEF and normal (n = 157) vs. high NP (n = 263) were younger, yet older than controls (n = 161), with an intermediate comorbidity profile. Normal NP HFpEF was associated with more left ventricular hypertrophy and worse diastolic function compared with controls, but better diastolic function, lower left atrial volumes, superior right ventricular function, and less mitral/tricuspid regurgitation compared with high NP HFpEF. Cardiac output (CO) reserve with exercise was preserved in normal NP HFpEF [101% predicted, interquartile range (IQR): 75-124%], but this was achieved only at the cost of higher left ventricular transmural pressure (LVTMP) (14 +/- 6 mmHg vs. 7 +/- 4 mmHg in controls, P < 0.001). In contrast, CO reserve was decreased in high NP HFpEF (85% predicted, IQR: 59-109%), with lower LVTMP (10 +/- 8 mmHg) compared with normal NP HFpEF (P < 0.001), despite similar PAWP. Patients with high NP HFpEF displayed the highest event rates, but normal NP HFpEF still had 2.7-fold higher risk for mortality or HF readmissions compared with controls (hazard ratio: 2.74, 95% confidence interval: 1.02-7.32) after adjusting for age, sex, and body mass index. Conclusion Patients with HFpEF and normal NP display mild diastolic dysfunction and preserved CO reserve during exercise, despite marked elevation in filling pressures. While clinical outcomes are not as poor compared with patients with high NP, patients with normal NP HFpEF exhibit increased risk of death or HF readmissions compared with patients without HF, emphasizing the importance of this phenotype. Key question What is the prognosis of patients with heart failure and preserved ejection fraction (HFpEF) who have normal natriuretic peptide (NP) levels? How does this group present in terms of cardiac structure and function, and haemodynamics at rest and during exercise? Key finding Patients with HFpEF and normal NP levels have increased mortality and heart failure readmissions compared with subjects with non-cardiac dyspnoea. Heart failure and preserved ejection fraction with elevated vs. normal NP levels is associated with worse right ventricular function, more secondary valve regurgitation, and impaired cardiac output reserve. Take-home message A considerable number of patients with HFpEF present with normal NP levels. Those patients exhibit increased morbidity and mortality in comparison with patients without heart failure, emphasizing the importance of this phenotype.
Notes: Borlaug, BA (corresponding author), Mayo Clin, Dept Cardiovasc Dis, Rochester, MN 55905 USA.
borlaug.barry@mayo.edu
Keywords: Diastolic heart failure;Exercise tolerance;Mortality;Natriuretic peptides;Obesity
Document URI: http://hdl.handle.net/1942/36834
ISSN: 0195-668X
e-ISSN: 1522-9645
DOI: 10.1093/eurheartj/ehab911
ISI #: WOS:000756779100001
Rights: The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Show full item record

WEB OF SCIENCETM
Citations

62
checked on Mar 29, 2024

Page view(s)

20
checked on Sep 7, 2022

Download(s)

4
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.